Targeting the AMPK pathway for the treatment of Type 2 diabetes. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Frontiers in bioscience : a journal and virtual library Année : 2009

Targeting the AMPK pathway for the treatment of Type 2 diabetes.

Benoît Viollet
Connectez-vous pour contacter l'auteur
Louise Lantier
Sophie Hébrard
  • Fonction : Auteur
Rémi Mounier
Marc Foretz

Résumé

Type 2 diabetes is one of the fastest growing public health problems worldwide, resulting from both genetic factors and inadequate adaptation to environmental changes. It is characterized by abnormal glucose and lipid metabolism due in part to resistance to the actions of insulin in skeletal muscle, liver and fat. AMP-activated protein kinase (AMPK), a phylogenetically conserved serine/threonine protein kinase, acts as an integrator of regulatory signals monitoring systemic and cellular energy status. The growing realization that AMPK regulates the coordination of anabolic and catabolic metabolic processes represents an attractive concept for type 2 diabetes therapy. Recent findings showing that pharmacological activation of AMPK improves blood glucose homeostasis, lipid profile and blood pressure in insulin-resistant rodents suggest that this kinase could be a novel therapeutic target in the treatment of type 2 diabetes. Consistent with these results, physical exercise and major classes of antidiabetic drugs have recently been reported to activate AMPK. In the present review, we update these topics and discuss the concept of targeting the AMPK pathway for the treatment of type 2 diabetes.
Fichier principal
Vignette du fichier
Figures_3_4_correct.pdf (1.02 Mo) Télécharger le fichier
AMPK_diabetes_FBS.pdf (661.35 Ko) Télécharger le fichier
inserm-00367501_edited.pdf (508.94 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Origine : Fichiers produits par l'(les) auteur(s)
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

inserm-00367501 , version 1 (11-03-2009)

Identifiants

  • HAL Id : inserm-00367501 , version 1
  • PUBMED : 19273282

Citer

Benoît Viollet, Louise Lantier, Jocelyne Devin-Leclerc, Sophie Hébrard, Chloé Amouyal, et al.. Targeting the AMPK pathway for the treatment of Type 2 diabetes.. Frontiers in bioscience : a journal and virtual library, 2009, 14, pp.3380-400. ⟨inserm-00367501⟩
180 Consultations
1664 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More